KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.65

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$86.97M
EPS-2.8500
P/E Ratio-2.97
Earnings Date08/12/2026

klrs

Short Term Debt

Last Annual Value

316.00K

3-Year CAGR

%

5-Year CAGR

-37%

10-Year CAGR

-21%

KT

Kalaris Therapeutics Inc Competitors Analysis of Short Term Debt

KLRS · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
316.00K
N/A-45.5%N/A 
0.00
N/AN/AN/A
3.06M
N/AN/AN/A
0.00
N/AN/AN/A
112.06K
N/AN/AN/A
6.03M
20.7%N/AN/A
0.00
N/AN/AN/A
5.22M
N/AN/AN/A
5.10M
23.2%-20.2%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.65, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.65